On January 28, 2026, Evercore ISI maintained its “Outperform” rating for Danaher Corporation and raised its price target marginally, underscoring continued confidence in the company’s long-term trajectory. The brokerage cited Danaher’s diversified exposure across Life Sciences, Diagnostics and Biotechnology as key competitive advantages, noting the firm’s disciplined capital deployment and robust R&D pipeline as drivers of sustained market leadership.

Danaher reported fourth-quarter adjusted earnings per share of $2.23, narrowly topping the Zacks Consensus Estimate of $2.22. Net sales reached $6.84 billion, surpassing expectations of $6.79 billion and marking a 4.5% year-over-year increase. Growth was led by the Biotechnology segment, which delivered a 9% revenue uptick, and the Diagnostics segment, which saw profits climb by 14.3%. Foreign-currency translation added approximately 2.5% to reported sales, while recent acquisitions and divestitures had a modest 0.5% drag.

For the full year 2025, Danaher achieved net revenues of $24.6 billion, representing a 3% increase from the prior year. Core sales advanced 2.5% in the fourth quarter, reflecting sustained end-market momentum. Looking ahead to the first quarter of 2026, management projects low single-digit core sales growth and adjusted EPS in a range between $8.35 and $8.50. This guidance reflects confidence in Danaher’s ability to leverage its innovation pipeline and operational efficiencies amid evolving market dynamics.